Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer

The recent manuscript in New England Journal of Medicine by Antonarakis et al.1 has important clinical implications. This study evaluates mRNA expression of a particular androgen receptor splice variant-7 (AR-V7), in circulating tumor cells (CTCs) from metastatic castrate-resistant prostate cancer (...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartor, Oliver, Dong, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Invited Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430945/
https://www.ncbi.nlm.nih.gov/pubmed/25532583
http://dx.doi.org/10.4103/1008-682X.145069
_version_ 1782371258810236928
author Sartor, Oliver
Dong, Yan
author_facet Sartor, Oliver
Dong, Yan
author_sort Sartor, Oliver
collection PubMed
description The recent manuscript in New England Journal of Medicine by Antonarakis et al.1 has important clinical implications. This study evaluates mRNA expression of a particular androgen receptor splice variant-7 (AR-V7), in circulating tumor cells (CTCs) from metastatic castrate-resistant prostate cancer (mCRPC) patients receiving enzalutamide or abiraterone. The findings were striking, none of the 18 patients with detectable AR-V7 in CTCs had prostate-specific antigen (PSA) responses. Further, the median time to PSA progression after enzalutamide or abiraterone treatment was only 1.3–1.4 months in AR-V7-positive patients as compared to 5.3–6.1 months in AR-V7 negative patients. AR-V7 in CTCs was also associated with shorter survival.
format Online
Article
Text
id pubmed-4430945
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-44309452015-06-01 Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer Sartor, Oliver Dong, Yan Asian J Androl Invited Research Highlight The recent manuscript in New England Journal of Medicine by Antonarakis et al.1 has important clinical implications. This study evaluates mRNA expression of a particular androgen receptor splice variant-7 (AR-V7), in circulating tumor cells (CTCs) from metastatic castrate-resistant prostate cancer (mCRPC) patients receiving enzalutamide or abiraterone. The findings were striking, none of the 18 patients with detectable AR-V7 in CTCs had prostate-specific antigen (PSA) responses. Further, the median time to PSA progression after enzalutamide or abiraterone treatment was only 1.3–1.4 months in AR-V7-positive patients as compared to 5.3–6.1 months in AR-V7 negative patients. AR-V7 in CTCs was also associated with shorter survival. Medknow Publications & Media Pvt Ltd 2015 2014-12-12 /pmc/articles/PMC4430945/ /pubmed/25532583 http://dx.doi.org/10.4103/1008-682X.145069 Text en Copyright: © Asian Journal of Andrology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Invited Research Highlight
Sartor, Oliver
Dong, Yan
Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
title Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
title_full Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
title_fullStr Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
title_full_unstemmed Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
title_short Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
title_sort androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
topic Invited Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430945/
https://www.ncbi.nlm.nih.gov/pubmed/25532583
http://dx.doi.org/10.4103/1008-682X.145069
work_keys_str_mv AT sartoroliver androgenreceptorvariant7animportantpredictivebiomarkerincastrateresistantprostatecancer
AT dongyan androgenreceptorvariant7animportantpredictivebiomarkerincastrateresistantprostatecancer

Ejemplares similares